## Valentina Gambacorta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8283377/publications.pdf

Version: 2024-02-01

1478505 1474206 11 641 9 6 citations h-index g-index papers 11 11 11 1254 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse. Cancer Discovery, 2022, 12, 1449-1461.	9.4	26
2	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 147.	4.8	39
3	Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Frontiers in Cell and Developmental Biology, 2019, 7, 207.	3.7	32
4	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	12.8	120
5	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	30.7	253
6	Integrated Epigenetic Profiling Identifies EZH2 As a Therapeutic Target to Re-Establish Immune Recognition of Leukemia Relapses with Loss of HLA Class II Expression. Blood, 2019, 134, 514-514.	1.4	1
7	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	1.4	164
8	Exhausted Central Memory and Memory Stem T Cells Specific for Leukemia Infiltrate the Bone Marrow of AML Patients Relapsing after Allogeneic HSCT. Blood, 2018, 132, 2028-2028.	1.4	1
9	Multiple Inhibitory Receptors Are Expressed on Central Memory and Memory Stem T Cells Infiltrating the Bone Marrow of AML Patients Relapsing after Allo-HSCT. Blood, 2016, 128, 4564-4564.	1.4	3
10	Natural Killer Cell Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide: Elimination of Donor-Derived Mature Alloreactive NK Cells, but Favorable Conditions for Adoptive Immunotherapy. Blood, 2016, 128, 4567-4567.	1.4	0
11	HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics. Blood, 2015, 126, 743-743.	1.4	2